Denali Therapeutics Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Denali Therapeutics reported Q3 2026 AVLAYAH (Hunter syndrome therapy) net product revenue of $17.8 million in its second full commercial quarter, with Q4 2026 guidance of $30.0–$32.0 million. The company recognized a one-time $194.0 million net gain on the sale of a Priority Review Voucher, resulting in Q3 net income of $70.1 million. Cash and marketable securities totaled $1.0 billion as of September 30, 2026. The company is advancing zafinofusp alfa (Sanfilippo syndrome type A) toward a 2027 BLA submission, with five TransportVehicle programs expected to generate data in 2027.
Why this rating
AVLAYAH commercial launch tracking well; $194M voucher sale boosts cash but is non-recurring. Five pipeline programs on track. Moderate significance for $1.1B company; revenue growth meaningful but early-stage, one-time gain inflates profitability.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.